As of June 30, 2026, Curanex Pharmaceuticals Inc carries a market capitalization of 7.52M, placing it among publicly traded companies globally. Its enterprise value stands at 4.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.52M |
| Enterprise Value | 4.86M |
As of June 30, 2026, Curanex Pharmaceuticals Inc has 1.42M shares outstanding.
| Shares Outstanding | 1.42M |
These figures are as of June 30, 2026.
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | -0.61 |
| P/OCF Ratio | -0.61 |
As of June 30, 2026, Curanex Pharmaceuticals Inc maintains a current ratio of 45.95, meaning it holds 46.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.77, indicating elevated leverage, while an interest coverage ratio of -2,550.48 demonstrates limited ability to service its debt obligations.
| Current Ratio | 45.95 |
| Quick Ratio | 28.17 |
| Debt / Equity | 5.77 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -2,550.48 |
Over the twelve months ended June 30, 2026, Curanex Pharmaceuticals Inc posted a negative return on equity (ROE) of -411.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -357.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 6.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -411.10 |
| Return on Assets (ROA) | -357.22 |
| Employee Count | 6.00 |
As of the close on November 16, 2026, Curanex Pharmaceuticals Inc's stock has declined approximately 54.26% over the past 52 weeks. The 50-day moving average sits at 4.97, while the 200-day moving average is 6.10.
| 52-Week Price Change | -54.26% |
| 50-Day Moving Average | 4.97 |
| 200-Day Moving Average | 6.10 |
Over the twelve months ended June 30, 2026, Curanex Pharmaceuticals Inc generated - - in revenue and converted that into -10.47M in net income, yielding earnings per share of -7.57. EBITDA reached -10.43M, while operating income came in at -10.55M.
| Operating Income | -10.55M |
| Pretax Income | -10.47M |
| Net Income | -10.47M |
| EBITDA | -10.43M |
| EBIT | -10.55M |
| Earnings Per Share (EPS) | -7.57 |
As of June 30, 2026, Curanex Pharmaceuticals Inc holds 2.94M in cash and equivalents against 276,359.00 in total debt, resulting in a net debt position of -2.94M. Total book value stands at 4.79M, with working capital of 4.69M providing operational flexibility.
| Cash & Cash Equivalents | 2.94M |
| Total Debt | 276,359.00 |
| Net Debt | -2.94M |
| Equity (Book Value) | 4.79M |
| Book Value Per Share | 3.38 |
| Working Capital | 4.69M |
Curanex Pharmaceuticals Inc produced -12.08M in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -12.08M |
| Free Cash Flow | -12.08M |
| FCF Per Share | -8.73 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -164.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -198.19, meaning Curanex Pharmaceuticals Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -198.19 |
| FCF Yield | -164.65 |
Curanex Pharmaceuticals Inc's most recent stock split took place on August 20, 2026 with a 20:1 split ratio.
| Last Split Date | 8/20/2026 |
| Split Ratio | 20:1 |
As of June 30, 2026, Curanex Pharmaceuticals Inc has an Altman Z-Score of 6.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.90 |